stockrowIndivior Pharmaceuticals Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.
- Revenue
- +13.4%
- EPS
- +241.5%
- Free cash flow
- +240.7%
- Total debt
- +51.6%
Quarter to September 2026, against a year earlier
Follow SUPN
Alert me
Indivior Pharmaceuticals Inc. (SUPN) P/B ratio
Indivior Pharmaceuticals Inc. has no meaningful P/B ratio: its trailing twelve-month book value is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 299× (April 2024) — the current reading is the lowest in ten years.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 59.3× | 378.97% |
| FY2021 | 12.4× | (5.53%) |
| FY2020 | 13.1× | 621.13% |
| FY2019 | 1.8× | (87.78%) |
| FY2018 | 14.9× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| SUPN Indivior Pharmaceuticals Inc. | n/m |
| RDY Dr. Reddy's Laboratories Ltd compare | 3.0× |
| ALKS Alkermes plc compare | 4.0× |
| LNTH Lantheus Holdings, Inc. compare | 4.9× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 9.7× |
| AMLX Amylyx Pharmaceuticals, Inc. compare | 12.9× |
| HIMS Hims & Hers Health, Inc. compare | 17.2× |
| LQDA Liquidia Corporation compare | 20.4× |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 59.5× |
| Drug Manufacturers Specialty & Generic industry median | 1.8× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on SUPN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement